Physician profile
Walter Y Tsang
NPI 1285861799
$25,267.58
in general payments reported to CMS, 2019-2025
66 companies · $4,786 in 2025
The $4,786 reported for 2025 was more than what 81% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,042 · 2020: $1,048 · 2021: $3,612 · 2022: $4,262 · 2023: $6,394 · 2024: $4,124 · 2025: $4,786.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Consulting Fee: $2,200 · Education: $907 · Long Term Medical Supply Or Device Loan: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,030.33 |
| Consulting Fee | $2,200.00 |
| Education | $906.88 |
| Long Term Medical Supply Or Device Loan | $166.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $3,545.75 | 2019-2025 | |
| Taiho Oncology, INC. | $2,448.30 | 2021-2025 | |
| Pfizer INC. | $2,331.13 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,039.78 | 2019-2025 | Ninlaro, Iclusig, Alunbrig |
| Astellas Pharma US INC | $960.48 | 2019-2025 | Xtandi, Vyloy, Xospata |
| E.R. Squibb & Sons, L.L.C. | $952.04 | 2019-2025 | Opdivo, Opdualag, Reblozyl |
| Celgene Corporation | $918.90 | 2021-2025 | Reblozyl, Pomalyst, Opdualag |
| Astrazeneca Pharmaceuticals Lp | $859.71 | 2020-2025 | Calquence, Tagrisso, Imfinzi |
| Sobi, INC | $775.69 | 2022-2025 | |
| Lilly USA, LLC | $681.52 | 2021-2025 | Jaypirca, Verzenio, Retevmo |
| Bayer Healthcare Pharmaceuticals INC. | $681.05 | 2019-2025 | |
| Gilead Sciences, INC. | $673.71 | 2021-2025 | Trodelvy |
| Alexion Pharmaceuticals, INC. | $664.15 | 2019-2025 | Ultomiris |
| Eisai INC. | $628.96 | 2021-2025 | |
| Puma Biotechnology, INC. | $559.67 | 2019-2025 | Nerlynx |
Show all 66 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $509.40 | 2022-2025 | Zejula, Ojjaara, Shingrix |
| Janssen Biotech, INC. | $488.54 | 2019-2025 | Rybrevant, Carvykti |
| Amgen INC. | $476.63 | 2019-2025 | Lumakras, Blincyto, Kyprolis |
| Merck Sharp & Dohme LLC | $450.32 | 2020-2025 | Keytruda, Lynparza, Welireg |
| Array Biopharma INC | $419.93 | 2021-2025 | Braftovi, Mektovi, Tukysa |
| Genzyme Corporation | $414.24 | 2019-2023 | |
| Genentech USA, INC. | $398.48 | 2021-2025 | Tecentriq, Itovebi, Phesgo |
| Seagen INC. | $380.48 | 2020-2025 | Adcetris, Tivdak |
| Ipsen Biopharmaceuticals, INC | $287.54 | 2019-2023 | Tazverik |
| Pharmacyclics LLC, An Abbvie Company | $261.76 | 2019-2023 | Imbruvica |
| Karyopharm Therapeutics INC. | $259.04 | 2022-2025 | Xpovio |
| Emd Serono, INC. | $257.76 | 2021-2024 | Tepmetko, Bavencio |
| Beigene USA, INC. | $256.24 | 2020-2024 | Brukinsa |
| Blueprint Medicines Corporation | $210.71 | 2021-2024 | Ayvakit |
| Incyte Corporation | $199.31 | 2019-2023 | Jakafi |
| Aveo Pharmaceuticals, INC. | $187.47 | 2022-2025 | Fotivda |
| Myovant Sciences INC. | $173.59 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $152.47 | 2019-2025 | |
| Beone Medicines USA, INC. | $132.16 | 2025 | Brukinsa |
| Adaptive Biotechnologies Corporation | $117.71 | 2024-2025 | Clonoseq |
| Dova Pharmaceuticals | $117.16 | 2019-2021 | |
| Daiichi Sankyo INC. | $117.00 | 2021-2025 | Enhertu, Datroway |
| Pharmaessentia USA Corporation | $113.75 | 2025 | Besremi |
| Stemline Therapeutics INC. | $109.57 | 2023-2024 | Orserdu |
| Abbvie INC. | $89.21 | 2023-2025 | Venclexta |
| Legend Biotech USA INC. | $86.66 | 2024-2025 | Carvykti |
| Secura Bio, INC. | $84.29 | 2019-2024 | Copiktra |
| Regeneron Healthcare Solutions, INC. | $77.87 | 2024 | Libtayo |
| Exelixis INC. | $72.36 | 2022-2023 | Cabometyx |
| Spectrum Pharmaceuticals INC. | $70.57 | 2025 | Rolvedon |
| Geron Corporation | $50.26 | 2025 | Rytelo |
| Adc Therapeutics America, INC. | $46.98 | 2023 | |
| Rigel Pharmaceuticals, INC. | $42.00 | 2024-2025 | Rezlidhia, Tavalisse, Gavreto |
| Tg Therapeutics, INC. | $38.93 | 2021-2022 | |
| Epizyme, INC. | $38.10 | 2021 | |
| Global Blood Therapeutics, INC. | $30.91 | 2020 | |
| Blue Earth Diagnostics | $29.29 | 2022 | |
| Apellis Pharmaceuticals, INC. | $27.27 | 2023 | Empaveli |
| Sumitomo Pharma America, INC. | $26.95 | 2023-2024 | Orgovyx |
| Sun Pharmaceutical Industries INC. | $25.75 | 2022 | |
| Agios Pharmaceuticals, INC. | $25.21 | 2024 | Pyrukynd |
| Jazz Pharmaceuticals INC. | $22.89 | 2024 | |
| Myriad Genetic Laboratories, INC. | $22.31 | 2022 | |
| Immunogen, INC. | $21.14 | 2023 | Elahere |
| Acrotech Biopharma INC. | $20.54 | 2021 | |
| Mirati Therapeutics, INC. | $20.34 | 2023 | Krazati |
| Novocure INC. | $19.51 | 2023 | Optune |
| Advanced Accelerator Applications | $18.37 | 2020 | |
| Alnylam Pharmaceuticals INC. | $17.49 | 2020 | |
| Kite Pharma, INC. | $16.38 | 2025 | Yescarta |
| Emmaus Medical, INC. | $13.90 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Walter Tsang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.